Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 23Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Lymphoma, Mantle-Cell 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

Doxorubicin 17Ifosfamide 16Radiotherapy 10Filgrastim 5Imatinib Mesylate 4Etoposide 4Chemotherapy, Adjuvant 4pazopanib 3Vincristine 3Neoadjuvant Therapy 3Dactinomycin 3Cyclophosphamide 3Carboplatin 3pegfilgrastim 2cixutumumab 2brostallicin 2belinostat 2Trabectedin 2Sunitinib 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Epirubicin 2Diathermy 2temsirolimus 1soblidotin 1selinexor 1saracatinib 1romidepsin 1ribociclib 1reolysin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrosarcoma × temsirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡